Vaccination has become an important therapeutic approach to the treatment of Alzheimer's disease (AD), however, immunization with Aβ amyloid can have unwanted, potentially lethal, side effects. Here we demonstrate an alternative peptide-mimotope vaccine strategy using the SDPM1 peptide. SDPM1 is a 20 amino acid peptide bounded by cysteines that binds tetramer forms of Aβ 1-40 -and Aβ 1-42 -amyloids and blocks subsequent Aβ amyloid aggregation. Immunization of mice with SDPM1 induced peptide-mimotope antibodies with the same biological activity as the SDPM1 peptide. When done prior to the onset of amyloid plaque formation, SDPM1 vaccination of APPswePSEN1(A246E) transgenic mice reduced amyloid plaque burden and Aβ 1-40 and Aβ 1-42 levels in the brain, improved cognitive performance in Morris water maze tests, and resulted in no increased T cell responses to immunogenic or Aβ peptides or brain inflammation. When done after plaque burden was already significant, SDPM1 immunization still significantly reduced amyloid plaque burden and Aβ 1-40/1-42 peptide levels in APPswePSEN1(A246E) brain without inducing encephalitogenic T cell responses or brain inflammation, but treatment at this stage did not improve cognitive function. These experiments demonstrate the efficacy of a novel vaccine approach for Alzheimer's disease where immunization with an Aβ 1-40/1-42 amyloid-specific binding and blocking peptide is used to inhibit the development of neuropathology and cognitive dysfunction.
Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly (Bachman et al., 1992) . The decline in cognitive abilities in AD is associated with pathologic changes in the brain, the most prevalent of which are neurofibrillary tangles and amyloid plaques (Selkoe, 2001) . Amyloid plaques, which occur at far greater levels in AD brain than in normal individuals, are one of the most robust pathologic hallmarks of AD (Terry, 1996) . Amyloid plaques are formed by the sequential cleavage of the amyloid precursor protein (APP) by β (BACE) and γ (Presenilin) secretases to create predominantly Aβ 1-40 or Aβ 1-42 peptides (Tabaton and Tamagno, 2007) . Once made, these Aβ peptides aggregate to create Aβ amyloid and ultimately contribute to the formation of amyloid plaques in the brain. A number of animal models bearing mutations in APP or presenilin 1 (PSEN1), both genes that when mutated can cause early onset forms of AD (Selkoe, 2001) , have been made that recapitulate amyloid plaque formation with associated synaptic and cognitive deficits (Games et al., 2006) . These monogenic or bigenic transgenic models, however, do not recapitulate the formation of neurofibrillary tangles or neurodegeneration, two important aspects of AD pathology (Jaworski et al., 2010) . Aβ amyloid formation involves the formation of quaternary protein structures, beginning with the dimerization of the Aβ 1-40 or Aβ 1-42 peptide and subsequent oligomerization that ultimately creates very high molecular weight protein aggregates. Many studies have demonstrated that various low molecular weight Aβ oligomeric forms are toxic to neurons (Bard et al., 2003; Barghorn et al., 2005; Cleary et al., 2005; Deshpande et al., 2006; Gong et al., 2003; Lambert et al., 1998; Noguchi et al., 2009; Selkoe, 2001; Shankar et al., 2008) . Aβ amyloid, being a pathologic protein structure, is also immunogenic; many AD patients have antibody titers against Aβ peptides or Aβ amyloid (Du et al., 2001; Geylis et al., 2005; Hyman et al., 2001; Nath et al., 2003; Weksler et al., 2002) . Indeed, some studies suggest that AD patients have lower anti-Aβ antibody titers than healthy elderly individuals and that higher titers may therefore be protective against development of AD (Du et al., 2001; Weksler et al., 2002) .
Consistent with this notion, one of the most promising approaches to treatment for AD has been to immunize patients with Aβ 1-42 amyloid to stimulate immune clearance of amyloid plaques, an approach first described by Schenk et al. (1999) . This approach has
